www.medical-devices.tech
02
'23
Written on Modified on
Philips News
PHILIPS AND MASIMO INTRODUCE ADVANCED MONITORING CAPABILITIES TO PHILIPS HIGH ACUITY PATIENT MONITORS
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment.
Royal Philips and Masimo, a global medical technology company, announced FDA clearance allowing the activation of SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO₂ measurements in Philips Patient Monitors – IntelliVue MX750 and MX850.
Integrating the SedLine, O3® and CO₂ advanced Masimo measurements into Philips high acuity IntelliVue® MX series multi-parameter monitors can help clinicians assess and monitor blood saturation in the brain (cerebral oxygenation), anaesthetic sedation, and patient respiratory performance with ease, all from the same monitor. The data can also be shared between monitors. These capabilities and metrics help care providers act decisively while also helping to lower the cost of care by providing a more holistic view of the patient from one system.
Since establishing a partnership to improve patient care, outcomes and safety in 2016, Philips and Masimo have already introduced a variety of advanced monitoring capabilities to select IntelliVue® MX-series multi-parameter monitors. Today’s announcement reveals the expansion of O3 regional oximetry capability to Philips’ latest, high acuity MX750 and MX850 patient monitors, as well as the introduction of new SedLine Brain Function Monitoring and CO₂ measurement capabilities, adding versatility to Philips’ already robust portfolio of patient monitoring solutions that support clinical workflow, caregiver efficiencies, and enhanced patient care.
To learn more about Philips’ ongoing collaboration with Masimo to deliver on the future of continuous monitoring, visit www.philips.com/masimo.
www.philips.com